Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure ( COPE): A Pilot Study in Alcohol-dependent WomenShow others and affiliations
2017 (English)In: Journal of addiction medicine, ISSN 1932-0620, E-ISSN 1935-3227, Vol. 11, no 2, p. 119-125Article in journal (Refereed) Published
Abstract [en]
Objectives: Posttraumatic stress disorder (PTSD) and substance use disorders are highly comorbid. Effective treatments are largely lacking. This pilot study evaluated the safety and feasibility of a novel intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), in preparation for a randomized controlled trial. Methods: Twenty-two treatment-seeking women with current DSM-IV-TR PTSD and alcohol dependence (AD) were recruited. Participants received COPE. Safety and feasibility were evaluated, as were efficacy-related outcomes: PTSD and depression symptom severity, alcohol use, craving, and dependence severity. Results: No adverse events occurred. COPE was implemented in routine clinical practice. Among the assessed women, 95.8% were eligible to participate. Treatment attendance and completion were higher than in previous studies. Post treatment, all efficacy-related outcomes, including PTSD and depression symptom severity, alcohol use, craving, and dependence severity, were significantly reduced. Conclusions: COPE was safe and feasible to use. Concerns that trauma-focused, exposure-based therapy might promote relapse in this population appear unwarranted. Our findings provide initial evidence suggestive of COPE efficacy for comorbid PTSD and AD in women. These results provide a strong rationale for investigating the efficacy of COPE for comorbid PTSD and AD in women in a randomized controlled trial.
Place, publisher, year, edition, pages
LIPPINCOTT WILLIAMS & WILKINS , 2017. Vol. 11, no 2, p. 119-125
Keywords [en]
alcohol dependence; alcohol use disorder; integrated treatment; PTSD; women
National Category
Substance Abuse
Identifiers
URN: urn:nbn:se:liu:diva-136635DOI: 10.1097/ADM.0000000000000286ISI: 000397594900009PubMedID: 28079572OAI: oai:DiVA.org:liu-136635DiVA, id: diva2:1089849
Note
Funding Agencies|Swedish Society of Addiction Medicine; Systembolagets Alcohol Research Council; Soderstrom-Konigska Foundation
2017-04-212017-04-212017-05-23